Association Between Haptoglobin 2-2 Genotype and Coronary Artery Disease and Its Severity in a Tunisian Population
Haptoglobin (Hp) polymorphism generates three common human genotypes (Hp1-1, Hp2-1, and Hp2-2), having functional differences, related to the risk of development of cardiovascular diseases. These functions are a consequence of hemoglobin binding that leads to the synthesis of an antioxidant like ferritin. We explored the association of Hp polymorphism with significant coronary stenosis (SCS) and its severity within 400 Tunisian patients, using genotyping, biochemical parameters, and the Gensini score. After adjustments for age and gender, Hp2-2 was associated with the highest ferritin but the lowest Hp concentrations. After adjustments for confounding parameters, the OR of SCS associated with Hp2-2 was 1.74 (95% CI 1.18–2.58; p = 0.005). This effect was enhanced within diabetics (OR 1.90, 95% CI 1.11–3.24; p = 0.018), obese subjects (OR 1.98, 95% CI 1.10–4.86; p = 0.034), and smokers (OR 4.17, 95% CI 1.54–1.29; p = 0.005). The Hp2-2 genotype is associated with an increase in SCS especially in diabetics, the obese, and smokers.
KeywordsHaptoglobin Coronary artery disease Hp2-2 genotype Tunisia
We are grateful to Mrs. Elise Fletcher Nouira, EFL teacher, for her contribution in checking the manuscript language, and Mr. Chaabani H and Mrs. Haj Khellil A. We acknowledge the general director of Sahloul University Hospital and the excellent technical assistance of members of the Biochemistry Department of Sahloul University Hospital. We are especially grateful to the study participants. This study was funded by grants from the Tunisian Ministry of Higher Education, Scientific Research and Technology and the Tunisian Ministry of Health (LR 12 SP11); without their immense generosity and support, this study could not have been undertaken.
- Cahill LE, Levy AP, Chiuve SE, Jensen MK, Wang H, Shara NM, Blum S, Howard BV, Pai JK, Mukamal KJ, Rexrode KM, Rimm EB (2013) Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol 19:728–737CrossRefGoogle Scholar
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560–2572PubMedCrossRefGoogle Scholar
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRefGoogle Scholar
- Langlois M, Delanghe J, Philippé J, Ouyang J, Bernard D, De Buyzere M, Van Nooten G, Leroux-Roels G et al (1997) Distribution of lymphocyte subsets in bone marrow and peripheral blood is associated with haptoglobin type. Eur J Clin Chem Clin 35:199–205Google Scholar
- Lioupis C, Barbatis C, Drougou A, Koliaraki V, Mamalaki A, Klonaris C, Georgopoulos S, Andrikopoulos V, Bastounis E (2011) Association of haptoglobin genotype and common cardiovascular risk factors with the amount of iron in atherosclerotic carotid plaques. Atherosclerosis 216:131–138PubMedCrossRefGoogle Scholar
- Liu HB, Shi YP, Guo XF, Shan J, Xu G (2011) Association of haptoglobin 1/2 polymorphism with coronary heart disease in Chinese. Chin J Med Genet 28:60–63Google Scholar
- Suleiman M, Aronson D, Asleh R, Kapeliovich MR, Roguin A, Meisel SR, Shochat M, Sulieman A, Reisner SA, Markiewicz W, Hammerman H, Lotan R, Levy NS, Levy AP (2005) Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 54:2802–2806PubMedCrossRefGoogle Scholar
- World Health Organization (1995) Physical status: the use and interpretation anthropometry: report of a WHO expert committee, WHO Technical Report Series. WHO, Geneva 854:321–344 Google Scholar